AURA · Aura Biosciences, Inc.
The latest filing states the doubt was alleviated.
“As disclosed in the Company's audited consolidated financial statements as of and for the year ended December 31, 2025, events and conditions existed which raised substantial doubt about the Company's ability to continue as a going concern, primarily due to recurring operating losses, negative cash flows from operations and liquidity constraints. Subsequent to year end, the Company completed the 2026 Follow-On Offering, raising approximately $241.8 million in net proceeds after completion of the Matrix Repurchase. Based on the successful execution of this financing, management has concluded that the events and conditions that previously raised substantial doubt have been alleviated.”View the 10-Q filed May 11, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-07 | Bender Jeremy |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-07-07 | Bender Jeremy |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2026-07-07 | Bender Jeremy |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
30,000 |
| 2026-07-01 | Kilroy Conor |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in two substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
14,858 |
| 2026-06-16 | Gibney Anthony S |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Common Stock
|
12,824 |
| 2026-06-11 | Bitetti Teresa Marie |
President, OBU |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Common Stock
|
15,000 |
| 2026-06-11 | Srivastava Sapna |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Common Stock
|
15,000 |
| 2026-06-11 | Bitetti Teresa Marie |
President, OBU |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Stock Option (Right to Buy)
|
30,000 |
| 2026-06-11 | Johnson David Michael |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Common Stock
|
15,000 |
| 2026-06-11 | Mattessich Antony C. |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Stock Option (Right to Buy)
|
30,000 |
| 2026-06-11 | Srivastava Sapna |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Stock Option (Right to Buy)
|
30,000 |
| 2026-06-11 | Mattessich Antony C. |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Common Stock
|
15,000 |
| 2026-06-11 | Johnson David Michael |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Stock Option (Right to Buy)
|
30,000 |
| 2026-05-19 | Holles Natalie C. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration. |
Common Stock
|
553,844 |
| 2026-05-19 | Holles Natalie C. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
600,118 |
| 2026-05-19 | Holles Natalie C. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
2,169,103 |
| 2026-05-07 | Matrix Capital Management Company, LP |
10% Owner |
Sell↓
Filing footnotes — Common Stock, par value $0.00001 per share (Common Stock) (Indirect)
The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. |
Common Stock, par value $0.00001 per share (Common Stock)
(I)
|
6,922,870 |
| 2026-04-30 | Holles Natalie C. |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-04-16 | Kilroy Conor |
See Remarks |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
11,738 |
| 2026-03-02 | Gibney Anthony S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
128,755 |
| 2026-03-02 | Hopkins Janet Jill |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
89,056 |
| 2026-03-02 | Kilroy Conor |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
112,661 |
| 2026-03-02 | de los Pinos Elisabet |
Director, See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
166,000 |
| 2026-03-02 | Elazzouzi Amy |
Senior Vice President, Finance |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
44,528 |
| 2026-03-02 | Plavsic Mark |
Chief Technical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
62,339 |
| 2026-03-02 | Elazzouzi Amy |
Senior Vice President, Finance |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
80,472 |
| 2026-03-02 | de los Pinos Elisabet |
Director, See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
249,000 |
| 2026-03-02 | Hopkins Janet Jill |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
160,944 |
| 2026-03-02 | Gibney Anthony S |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
71,245 |
| 2026-03-02 | Kilroy Conor |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
Common Stock
|
62,339 |
| 2026-03-02 | Plavsic Mark |
Chief Technical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Stock Option (Right to Buy)
|
112,661 |
| 2026-02-17 | Hopkins Janet Jill |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
20,401 |
| 2026-02-17 | Elazzouzi Amy |
Senior Vice President, Finance |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
8,549 |
| 2026-02-17 | de los Pinos Elisabet |
Director, See Remarks |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
47,648 |
| 2026-02-17 | Plavsic Mark |
Chief Technical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
15,890 |
| 2026-02-17 | Kilroy Conor |
See Remarks |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
12,079 |
| 2026-01-20 | de los Pinos Elisabet |
Director, See Remarks |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
16,928 |
| 2026-01-20 | Elazzouzi Amy |
Senior Vice President, Finance |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Common Stock
|
1,581 |
| 2025-11-17 | Hopkins Janet Jill |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.42 to $5.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
17,109 |
| 2025-10-29 | Elazzouzi Amy |
Senior Vice President, Finance |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Common Stock
|
896 |
| 2025-10-29 | de los Pinos Elisabet |
Director, See Remarks |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Common Stock
|
9,049 |
| 2025-10-16 | Plavsic Mark |
Chief Technical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Common Stock
|
12,169 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↑
Filing footnotes — Common Stock (Direct)
On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. |
Common Stock
|
2,554 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↑
Filing footnotes — Common Stock (Direct)
On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. |
Common Stock
|
1,094 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↑
Filing footnotes — Common Stock (Direct)
On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. |
Common Stock
|
4,744 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↑
Filing footnotes — Common Stock (Direct)
On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. |
Common Stock
|
547 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↑
Filing footnotes — Common Stock (Direct)
On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. |
Common Stock
|
1,094 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↑
Filing footnotes — Common Stock (Direct)
On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. |
Common Stock
|
2,319 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is fully vested. |
Stock Option (Right to Buy)
|
2,319 |
| 2025-08-18 | Elazzouzi Amy |
Senior Vice President, Finance |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is fully vested. |
Stock Option (Right to Buy)
|
1,094 |